1차 출처 기록
결정급탑라인 결과
Dogwood Therapeutics: Halneuron의 Phase 2b CINP 톱라인 결과, 2026년 가을 예정
The 8-K confirms the Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain remains on track with 164 patients enrolled and top-line results guided for fall 2026. Separately, the FDA accepted the SP16 IND for a Phase 1b CIPPN study that will begin enrolling mid-2026.
핵심 사실
- 제출
- 2026년 5월 14일 PM 12:50
- 이벤트
- 탑라인 결과
- 방향
- 중립
- 출처
- SEC 8-K
- 신뢰도
- 출처 확인
- 등록 환자
- 164
출처 발췌
EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders - ALPHARETTA, Ga., May 14, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the